An interventional study of Blood draw for Lp(a) in Cardiovascular Disease and Lipoprotein(a), sponsored by Novartis Pharmaceuticals. Completed at 904 sites in 49 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-01-28.
Sponsored by Novartis Pharmaceuticals · Not applicable, Interventional, and Diagnostic
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's enrollment of 49,001 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Established CVD defined as one of the following:
Exclusion Criteria:
Patients with established Cardiovascular disease
Diagnostic Test: Blood draw for Lp(a)
Collect sample for Lipoprotein(a) testing
Also known as: In case retrospective laboratory data are not available, blood sampling will be performed to analyze Lp(a)
Percentage of patients with normal and elevated Lipoprotein(a) (Lp(a)) levels in patients with established Cardiovascular Disease (CVD)
Prevalence of normal and elevated Lp(a) levels in patients with established CVD
Time frame: At screening
Lipoprotein(a) (Lp(a)) values
Evaluate the median and other relevant statistics describing the distribution of Lp(a) within the normal range and elevated Lp(a) levels
Time frame: At screening
Lp(a) values by region and country
Evaluate the median and other relevant statistics describing the distribution of Lp(a) by region and country
Time frame: At screening
Low-density lipoprotein cholesterol (LDL(C)) values (corrected and uncorrected)
Evaluate the median and other relevant statistics describing the distribution of LDL-C (corrected and uncorrected) within the normal range and with elevated Lp(a) levels
Time frame: At screening
Showing the first 100 of 904 sites across 49 countries.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals